

William K. Rawson
Direct Dial: 202.637.2230
william.rawson@lw.com

555 Eleventh Street, N.W., Suite 1000
Washington, D.C. 20004-1304
Tel: +1.202.637.2200 Fax: +1.202.637.2201
www.lw.com

LATHAM & WATKINS LLP

FIRM / AFFILIATE OFFICES

Abu Dhabi	Moscow
Barcelona	Munich
Beijing	New Jersey
Boston	New York
Brussels	Orange County
Chicago	Paris
Doha	Riyadh
Dubai	Rome
Frankfurt	San Diego
Hamburg	San Francisco
Hong Kong	Shanghai
Houston	Silicon Valley
London	Singapore
Los Angeles	Tokyo
Madrid	Washington, D.C.
Milan	

August 29, 2011

Michael Babich, CHAP Project Manager
US Consumer Product Safety Commission
4330 East West Highway
Bethesda, MD 20814

RE: Chronic Hazard Advisory Panel (CHAP) for
Phthalates: Request to Present New Data

Dear Dr. Babich:

At the conclusion of the July CHAP meeting, ExxonMobil Chemical Company ("ExxonMobil") orally requested an opportunity for the lead research investigators at the Hamner Institutes for Health Sciences ("Hamner Institute") to present the results of their recent studies on DINP at the proposed CHAP meeting in November. We are now formally renewing this request by letter.

As you know, in response to some small, single-high-dose studies suggesting potential anti-androgen effects for DINP, ExxonMobil sponsored large, more definitive dose-response studies at the Hamner Institute. Some written information pertaining to the results of these studies was made available at the recent CHAP public meeting, but there was no opportunity to present the results of the studies orally, or to answer questions that CHAP members might have. The results of these studies provide important information that is highly relevant to the CHAP deliberations, particularly with respect to the CHAP's inquiry concerning DINP's potential to cause anti-androgen effects.

During the July CHAP public meeting, it was announced that four other researchers are scheduled to make scientific presentations during the November CHAP meeting. We feel that the Hamner Institute research and data will provide new and valuable research on the issue of the safety of DINP and should be considered on equal footing with that of other laboratories.

The CPSIA requires that the CHAP "review all relevant data, including the most recent, best-available, peer-reviewed, scientific studies of these phthalates and phthalate alternatives that employ objective data collection practices or employ other objective methods."
§ 108(a)(2)(b)(v). The studies conducted by the Hamner Institute constitute precisely that kind

LATHAM & WATKINS^{LLP}

of data. The Hamner Institute anticipates that its studies will be accepted for publication in a peer-reviewed journal by the end of September.

We make this request now so that the CHAP can be consulted and time be set aside on the agenda for the November meetings, and also so that the lead investigators at the Hamner Institute can make their travel arrangements. We would appreciate a prompt reply.

Thank you for considering this request.

Sincerely,

A handwritten signature in black ink that reads "William K. Rawson". The signature is written in a cursive style with a long, sweeping tail on the final letter.

William K. Rawson
of LATHAM & WATKINS LLP

cc: Robert J. Howell, CPSC